Biom’Up : recognized expertise in the field of collagen.
Listed on Euronext Paris Comp C since October 2017, raising €42m at IPO
HEMOBLAST™ Bellows: best-in-class active dry powder used to rapidly halt bleeding during surgery (hemostasis).
PMA obtained from the FDA in December 2017, 7 months ahead of schedule and CE marked.
Top-up financing to complement IPO proceeds and accelerate the scale-up of the company. Biom’Up will also aim to expand its product portfolio with HEMOSNOW™.
Bryan, Garnier & Co acted as Sole Global Coordinator and Joint Bookrunner on this financing after leading the IPO
Financing in excess of €40m combining a capital increase and a bond issuance
Public offering raising €16m at €11.00 per share or a discount of 5% to the 3 day VWAP preceding launch
Issuance of bonds to Athyrium Capital Management, a leading US healthcare investor, for an initial amount of €25m that may subsequently be increased to €35m
Biom’Up received strong support from institutional investors which entered at the time of IPO and from new investors in Europe and the US
First healthcare ECM transaction on Euronext in 2018
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life. Its flagship product, HEMOBLAST™ Bellows, is a unique hemostatic solution, ready to use (no preparation time needed, no need to mix, no heat required), usable once or several times during the surgery. Developed by a world-renowned scientific team, HEMOBLAST™ Bellows has obtained positive results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412 patients in the United States. HEMOBLAST™ Bellows obtained its CE Mark in December 2016, and its PMA (Pre-Market Approval) application was granted by the FDA (Food & Drug Administration) in December 2017 with a view to commercializing in the United States over the summer in 2018. Since its creation, Biom’Up has benefited from the support of prominent European investors such as Bpifrance, Innobio, GIMV, Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the Company’s managers, who have invested €2 million in equity. Biom'Up successfully completed its IPO on Euronext Paris, raising 42.5 million euros in October 2017.
About Athyrium Capital Management
Athyrium Capital Management, LP ("Athyrium") is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. As of September 30, 2017, Athyrium had over $3.5 billion of assets under management. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, and healthcare focused services. The team partners with management teams to implement creative financing solutions to companies' capital needs.
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich and New York. The firm is a member of the London Stock Exchange and Euronext.
T: +33 1 70 36 57 22
T:+33 1 56 68 75 17
Anne Moore, PhD
T: +33 1 56 68 75 39
Jean de Pracomtal
T: +33 1 56 68 75 38